Identification and Development of Therapeutics for COVID-19

  title={Identification and Development of Therapeutics for COVID-19},
  author={Halie M. Rando and Nils Wellhausen and Soumita Ghosh and Alexandra J. Lee and Anna Ada Dattoli and Fenglin Hu and James Brian Byrd and Diane N. Rafizadeh and Yanjun Qi and Yuchen Sun and Jeffrey M. Field and Marouen Ben Guebila and Nafisa M. Jadavji and Ronan Lordan and Ashwin N. Skelly and Bharath Ramsundar and Christian Brueffer and Jinhui Wang and Rishi Raj Goel and YoSon Park and COVID-19 Review Consortium and Simina Maria Boca and Anthony Gitter and Casey S. Greene},
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory… 

Figures and Tables from this paper

An Open-Publishing Response to the COVID-19 Infodemic
This project illustrates the power of open publishing to organize both technical and non-technical scientists to aggregate and disseminate information in response to an evolving crisis.
The Current Use and Evolving Landscape of Nutraceuticals
The Role of Herbal and Nutritional Treatments in the Fight against COVID-19 and Other Respiratory Tract Infections
Studies assessing the roles of Chinese traditional medicine and nutrition in upper respiratory infections, including COVID-19, are reviewed, with promising findings reported when medical treatments were complemented with nutritional interventions.


Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
  • Ravikirti, R. Roy, A. Sarfaraz
  • Medicine
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2021
Inclusion of ivermectin in treatment regimen of mild to moderate COVID-19 patients could not be said with certainty based on study results as it had shown only marginal benefit in successful discharge from the hospital with no other observed benefits.
A critical overview of computational approaches employed for COVID-19 drug discovery
It is proposed that truly impactful computational tools must deliver actionable, experimentally testable hypotheses enabling the discovery of novel drugs and drug combinations, and that open science and rapid sharing of research results are critical to accelerate the development of novel, much needed therapeutics for COVID-19.
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies
It is suggested that ivermectin may offer beneficial effects towards Covid‐19 outcomes, and more randomized clinical trial studies are still needed to confirm the results.
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and is not a viable option to treat patients.
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Ivermectin should be validated in larger, appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities.
Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
Low to moderate-certainty evidence suggests reductions in covid-19 deaths and infections may be possible by using ivermectin, and the apparent safety and low cost suggest that iverMectin could have an impact on the SARS-CoV-2 pandemic globally.